|
 |
Last Updated: Apr 14, 2008 - 2:04:51 PM |
Latest Research
:
Cancer
:
Liver Cancer
Sunitinib slows tumor growth and metastasis in hepatocellular carcinoma
Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver, researchers report.
Apr 14, 2008 - 2:01:16 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Combined stenting and photodynamic therapy may improve survival rates in liver cancer
A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
Mar 11, 2008 - 3:40:58 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Percutaneous radiofrequency ablation of liver tumors prove safe and effective
Percutaneous imaging guided radiofrequency ablation (RFA) of hepatocellular carcinoma is a safe and effective technique, with benefits such as reduced post-procedural pain and length of hospital stay, according to a study conducted by researchers from Changi General Hospital in Singapore.
May 5, 2007 - 2:14:26 AM
|
Latest Research
:
Cancer
:
Liver Cancer
Cancer cells metastatic to the liver are a perfect target for gene therapy, study reports
A featured paper in the February 14 issue of Nature Cancer Gene Therapy demonstrates that cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based upon a fundamental new understanding of the differences between cancerous and normal liver cells. The findings signal a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.
Feb 15, 2007 - 3:28:37 AM
|
Latest Research
:
Cancer
:
Liver Cancer
Nexavar shown to significantly extend survival for patients with advanced liver cancer
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that an independent data monitoring committee (DMC) has reviewed the safety and efficacy data from the companies' pivotal Phase 3 trial in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. Based on this planned interim analysis, the DMC has concluded that the trial met its primary endpoint resulting in superior overall survival (OS) in those patients receiving Nexavar® (sorafenib) tablets versus those patients receiving placebo. The DMC also noted that there was no demonstrated difference in serious adverse event rates between the two treatment arms (Nexavar and placebo). Based on these conclusions, the DMC recommended that the trial be stopped early.
Feb 12, 2007 - 9:09:17 AM
|
Latest Research
:
Cancer
:
Liver Cancer
Colchicine can delay the development of hepatocellular carcinoma
Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study.
Sep 11, 2006 - 4:22:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Study implicates two human genes in liver cancer
By generating tumors in laboratory mice that mimic human liver cancer and by comparing the DNA of mouse and human tumors, researchers at Cold Spring Harbor Laboratory have identified two genes that are likely to play a role in the third leading cause of human cancer deaths. The study also establishes an efficient and adaptable method for exploring the biology of liver cancer, for validating potential therapeutic targets, and for testing new treatments.
Jun 29, 2006 - 2:40:00 AM
|
Latest Research
:
Cancer
:
Liver Cancer
Skin rash after lapatinib for liver cancer determines survival
In a study of a new chemotherapy drug for liver cancer, researchers found that the development of a skin rash correlated directly with the patient's response to treatment. Patients who developed a rash lived twice as long as those who did not, according to a study led by researchers at the University of Pittsburgh Cancer Institute presented today at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting in Atlanta.
Jun 5, 2006 - 4:25:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Liquorice compounds could be a key component for liver cancer treatment
Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment, reports Lisa Richards in Chemistry & Industry magazine.
Jun 5, 2006 - 4:13:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Pre-screening before chemotherapy recommended to avoid worst liver damage
Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston. While surgery to remove liver metastases also has proven beneficial, both of the most commonly used chemotherapy drugs to treat these tumors can seriously injure the liver the researchers report in the May 1 issue of the Journal of Clinical Oncology. Furthermore the damage caused to the liver by these preoperative chemotherapy regimens can adversely affects long-term surgical outcomes.
May 1, 2006 - 12:30:00 AM
|
Latest Research
:
Cancer
:
Liver Cancer
New technology to detect early liver cancer
Scientists have discovered a technology to detect liver cancer early, which they say could potentially save lives because its treatment is more effective if started early.
Jan 31, 2006 - 6:48:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Enzyme deficiency may contribute to liver cancer
Primary liver cancer is much more likely to take root when a naturally occurring enzyme is in short supply, a team of researchers has found at Mount Sinai Hospital's Samuel Lunenfeld Research Institute.
Jul 28, 2005 - 7:06:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Hepatitis B virus (HBV), hepatocellular carcinoma (HCC) and GSK-3beta
Researchers at The University of Texas M. D. Anderson Cancer Center have uncovered a crucial molecular link between a viral infection and development of a common and fatal form of liver cancer. In the process, they have identified a possible way to treat this disease as well as a number of other cancers.
Jul 22, 2005 - 1:05:00 AM
|
Latest Research
:
Cancer
:
Liver Cancer
Expandable Electrodes Useful Alternative to Surgery for Liver Tumors
The use of expandable electrodes with multiple tips in the treatment of liver tumors by radiofrequency ablation (RFA) is safe and effective, making it a useful alternative to surgery in selected patients, say researchers from the University of Brescia in Italy.
May 23, 2005 - 10:49:00 AM
|
Latest Research
:
Cancer
:
Liver Cancer
High levels of immunosuppressant may lead to tumor recurrence
A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.
Apr 25, 2005 - 10:47:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Radiofrequency (RF) ablation offers an effective first-line treatment for some liver cancer patients who are excluded from surgery
Liver cancer is the most common organ malignancy worldwide and generally carries a poor prognosis. Surgical resection removing the cancerous portion of the liver is considered the best hope for a cure. Unfortunately, most patients do not qualify for surgery. Liver transplantations are available for a small number of patients, but organ supply is limited, and tumor progression during the prolonged waiting period results in a high dropout rate. Consequently, RF ablation has emerged as an alternative treatment for inoperable liver cancer and may also be useful as a bridge to liver transplantation.
Feb 16, 2005 - 3:58:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Korean Study Examines Interaction of Risk Factors for Liver Cancer Mortality
Cigarette smoking, heavy alcohol consumption, and hepatitis B infection are all independent risk factors for death from liver cancer, but they do not interact synergistically, according to a new study.
Liver cancer is one of the most widespread cancers in the world, particularly in Asia and Africa where hepatitis and aflatoxin exposures are common. Risk factors include chronic alcohol consumption, cigarette smoking, dietary aflatoxin exposure, hepatitis B infection, and hepatic cirrhosis, but there has been limited exploration of the combined effects of these exposures.
Sun Ha Jee, Ph.D., M.H.S., of Yonsei University, in Seoul, Korea, and colleagues conducted a prospective cohort study of more than 1.2 million Korean men and women to assess the independent effects and interactions of three risk factors for liver cancer: cigarette smoking, heavy alcohol consumption, and hepatitis B infection. All three risk factors were independently associated with an increased risk of death from liver cancer, but there was no interaction between them.
Dec 16, 2004 - 7:21:00 PM
|
Latest Research
:
Cancer
:
Liver Cancer
Identifying the link between chronic hepatitis B infection and liver cancer may help cancer patients sidestep the poison of chemotherapy
Identifying the link between chronic hepatitis B infection and liver cancer may one day help cancer patients sidestep the poison of chemotherapy, a Purdue University study suggests.
The research group of Ourania M. Andrisani (oo-RAHN-ee-ah an-dri-SAH-nee) has shown that a protein the hepatitis virus instructs chronically infected liver cells to produce - known as the X protein - under certain conditions instructs precancerous infected liver cells to die. The discovery of how the X protein influences liver cell behavior could be harnessed as an anticancer therapy, turning the X protein's presence in the liver to patients' advantage.
Dec 16, 2004 - 6:12:00 PM
|
<< prev
next >>
|
